Edition:
United States

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

45.35USD
11:29am EDT
Change (% chg)

$0.15 (+0.33%)
Prev Close
$45.20
Open
$45.00
Day's High
$45.85
Day's Low
$44.45
Volume
52,488
Avg. Vol
237,084
52-wk High
$54.45
52-wk Low
$12.75

Latest Key Developments (Source: Significant Developments)

Atara Biotherapeutics prices public offering of stock at $35 per share​
Wednesday, 28 Feb 2018 09:30pm EST 

Feb 28 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.ATARA BIOTHERAPEUTICS - ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 4.3 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $35.00 PER SHARE​.  Full Article

Atara Says Commenced Underwritten Public Offering Of $150 Mln Shares Of Common Stock
Tuesday, 27 Feb 2018 04:01pm EST 

Feb 27 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.ATARA BIOTHERAPEUTICS - COMMENCED UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF ITS SHARES OF COMMON STOCK.  Full Article

Atara Biotherapeutics Posts Q4 Loss Of $1.15 Per Share
Tuesday, 27 Feb 2018 07:00am EST 

Feb 27 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.QTRLY LOSS PER SHARE $1.15.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DECEMBER 31, 2017 TOTALED $166.1 MILLION.Q4 EARNINGS PER SHARE VIEW $-1.14 -- THOMSON REUTERS I/B/E/S.  Full Article

Atara Biotherapeutics Says CFO Intends To Retire In April 2018
Wednesday, 21 Feb 2018 04:06pm EST 

Feb 21 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES CHIEF FINANCIAL OFFICER INTENTION TO RETIRE IN APRIL 2018.ATARA BIOTHERAPEUTICS INC - ‍JOHN MCGRATH, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, INTENDS TO RETIRE FROM CO AS OF APRIL 27, 2018​.  Full Article

Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study
Wednesday, 10 Jan 2018 08:00am EST 

Jan 10 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS.ATARA BIOTHERAPEUTICS INC - FIRST RESULTS FROM ATA188 PHASE 1 STUDY IN PATIENTS WITH PROGRESSIVE MS IN FIRST HALF OF 2019.  Full Article

Camber Capital Management Reports 6.7 Pct Passive Stake In Atara Biotherapeutics
Friday, 5 Jan 2018 12:26pm EST 

Jan 5 (Reuters) - CAMBER CAPITAL MANAGEMENT LLC ::CAMBER CAPITAL MANAGEMENT LLC REPORTS A 6.7 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS AS OF JANUARY 04 - SEC FILING.  Full Article

Atara Biotherapeutics prices public offering of 7 mln shares at $18.25 per share
Wednesday, 3 Jan 2018 10:55pm EST 

Jan 3 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.00 MILLION COMMON SHARES PRICED AT $18.25PER SHARE.  Full Article

Atara Biotherapeutics Announces Proposed Offering Of Common Stock
Tuesday, 2 Jan 2018 04:01pm EST 

Jan 2 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.ATARA BIOTHERAPEUTICS INC - ‍COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $100 MILLION OF ITS SHARES OF COMMON STOCK​.  Full Article

Atara Biotherapeutics Gets FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel
Friday, 29 Dec 2017 06:00am EST 

Dec 29 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO INITIATE TWO PHASE 3 CLINICAL STUDIES TO EVALUATE TABELECLEUCEL IN PATIENTS WITH RITUXIMAB-REFRACTORY EPSTEIN-BARR VIRUS ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (EBV+PTLD).ATARA BIOTHERAPEUTICS- RESULTS FROM FIRST TABELECLEUCEL PHASE 3 STUDY TO REACH PRIMARY ENDPOINT ARE EXPECTED TO BE ANNOUNCED IN FIRST HALF OF 2019.ATARA-‍PLANS TO SUBMIT TABELECLEUCEL CMA APPLICATION IN EU FOR PATIENTS WITH RITUXIMAB-REFRACTORY EBV+PTLD POST HEMATOPOIETIC CELL TRANSPLANT IN H1 2019.  Full Article

Morgan Stanley Reports 5 Pct Passive Stake In Atara Biotherapeutics As Of Nov 27
Thursday, 7 Dec 2017 05:44pm EST 

Dec 7 (Reuters) - Atara Biotherapeutics Inc ::MORGAN STANLEY REPORTS 5.0 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING.  Full Article

BRIEF-Atara Biotherapeutics Reports Q1 Loss Per Share $1.05

* ATARA BIOTHERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS